Photo: joker1991/Shutterstock.com Shareholder Claims Pharma Co. Exaggerated Success of Experimental Cancer Treatment
The shareholder derivative suit alleges 10 of the San Diego-based company's officers and directors intentionally gave investors nonspecific information and failed to disclose the risk factors of Pracinostat, a drug for which an international clinical trial was halted in July just before MEI's share price dropped more than 18% in a day.
October 22, 2020 at 05:39 PM
4 minute read
A shareholder has accused pharmaceutical company MEI Pharma Inc. of inflating stock prices by overhyping the trial success of a blood cancer treatment.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
